Recombinant Human Beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1)

What is the primary function of ST6GAL1?

ST6GAL1 is a Golgi-resident sialyltransferase that catalyzes the addition of α2,6-linked sialic acids to the terminal galactose of N-glycosylated proteins. Specifically, it generates α2,6 linkages of sialic acid on the non-reducing, terminal Galβ1-4GlcNAc residues of oligosaccharides and glycoconjugates . This sialylation modification affects glycoprotein structure and function, influencing numerous biological processes including cell-cell recognition, immune function, and receptor signaling.

How does ST6GAL1 differ from ST6GAL2?

While both enzymes are beta-galactoside alpha-2,6-sialyltransferases with 48.9% amino acid sequence identity, they differ significantly in expression patterns and substrate specificity:

ST6GAL1 has relatively broad substrate specificity, while ST6GAL2 shows more restricted activity and is primarily expressed in neural tissues .

How is ST6GAL1 expression altered in cancer?

ST6GAL1 is overexpressed in numerous cancer types, including breast, cervical, ovarian, prostate, pancreatic, colon, gastric, leukemia, hepatocellular carcinoma, and melanoma . This elevation is often attributed to gene amplification . In prostate cancer specifically, ST6GAL1 is significantly upregulated in cancer tissue compared to matched normal tissue, as verified in 200 patient samples .

What oncogenic signaling pathways are affected by ST6GAL1?

ST6GAL1 influences several key oncogenic pathways:

• PI3K/AKT pathway: ST6GAL1 enhances PI3K/AKT signaling in multiple cancer types, including colon, liver, ovarian, and breast cancers . This activation promotes invasion, proliferation, and epithelial-to-mesenchymal transition (EMT).

• EGFR signaling: ST6GAL1-mediated sialylation of EGFR has been linked to activation of PI3K/AKT signaling, increasing invasion and proliferation .

• TGF-β pathway: ST6GAL1 transcription and α2,6-sialylated N-glycans are upregulated during TGF-β-induced EMT, requiring the Sp1 element within the ST6GAL1 promoter .

How does ST6GAL1 contribute to chemoresistance in cancer?

Research has demonstrated that ST6GAL1 contributes to chemoresistance through multiple mechanisms:

• Cisplatin resistance: Cells that are resistant to cisplatin have upregulated endogenous ST6GAL1. Studies with ovarian cancer cell lines showed that cisplatin-resistant populations exhibited higher levels of ST6GAL1 compared to parental cells .

• Radiation resistance: ST6GAL1 has been shown to confer radiation resistance in colon cancer cell lines .

• Multidrug resistance: ST6GAL1 expression is associated with multidrug resistance in human acute myeloid leukemia .

The mechanisms likely involve ST6GAL1-mediated sialylation of specific receptors that influence survival signaling pathways.

How can recombinant ST6GAL1 be used in in vitro glycoengineering?

Recombinant ST6GAL1 can be used as a glycoengineering tool to modify glycoproteins in vitro . This has particular relevance for:

• Antibody engineering: Recombinant ST6GAL1 can be used to add α2,6-sialic acids to the Fc N-glycan of antibodies, which provides anti-inflammatory properties through a mechanism that remains under investigation .

• Studying structure-function relationships: By selectively modifying glycans on specific proteins, researchers can investigate how α2,6-sialylation affects protein function.

• Developing therapeutic glycoproteins: Controlled sialylation can optimize pharmacokinetic properties of therapeutic proteins.

The process typically involves incubating the target glycoprotein with recombinant ST6GAL1 and the donor substrate CMP-N-acetylneuraminate (CMP-sialic acid) under appropriate buffer conditions.

What are the optimal conditions for using recombinant ST6GAL1 in experimental settings?

Effective use of recombinant ST6GAL1 requires optimization of several parameters:

Additionally, for efficient Fc glycan α2,6-sialylation of IgG1, co-expression with both human α2,6-sialyltransferase 1 (ST6) and β1,4-galactosyltransferase 1 (GT) in CHO cells has been shown to be effective. Optimal plasmid ratios were determined to be 2% GT encoding plasmid and 20% ST6 encoding plasmid in the transfection mix .

How can the success of ST6GAL1-mediated sialylation be assessed?

Several complementary techniques can be used to confirm successful α2,6-sialylation:

• Lectin blotting: The Sambucus nigra lectin (SNA) specifically detects α2,6-sialylation, while Maackia amurensis lectin II (MALII) detects α2,3-sialylation .

• Mass spectrometry: LC-ESI-MS can be used to analyze Fc glycans and determine the extent of sialylation .

• Capillary zone electrophoresis isoelectric focusing (cIEF): This technique can assess the nature of sialic acid linkage following sequential sialidase digestions .

• Hydrophilic interaction liquid chromatography (HILIC): Provides detailed analysis of glycan structures .

How does extracellular ST6GAL1 differ from intracellular ST6GAL1 in function?

While canonically ST6GAL1 resides in the intracellular secretory apparatus and glycosylates nascent glycoproteins in biosynthetic transit, catalytically active ST6GAL1 is also released into the extracellular milieu. Research indicates that:

• Extracellular ST6GAL1 can extracellularly remodel cell surface and secreted glycans, representing a non-canonical mechanism of glycan modification .

• Extracellular ST6GAL1 from remote sources (such as the liver) can compensate for cellular ST6GAL1-mediated functions, including aggressive tumor cell proliferation and invasive behavior .

• Extracellular ST6GAL1 has been identified as a potent modifier of hematopoiesis, inflammatory cell production, B cell differentiation and proliferation, and in the sialylation of anti-inflammatory IgG .

These findings challenge traditional views of glycosylation as exclusively an intracellular process and suggest systemic glycan remodeling as a novel regulatory mechanism.

What structural elements of ST6GAL1 determine its substrate specificity?

Research on the structural determinants of ST6GAL1 substrate recognition has revealed:

• The N-terminal half of the polypeptide influences acceptor preference. Deletion of the transmembrane fragment induces loss of acceptor preference for specific glycoproteins .

• A peptide region of approximately 50 amino acids within the ST6GAL1 stem region governs both the preference for glycoprotein acceptors and catalytic activity, suggesting it exerts steric control on the catalytic domain .

• Progressive truncation of the N-terminus demonstrates that the catalytic domain can proceed with sialic acid transfer with increased efficiency until 80 amino acids are deleted .

• When the ST6GAL1 catalytic domain is fused to the N-terminal half of an unrelated transferase (core 2 β1,6-N-acetylglucosaminyltransferase), a chimeric form with broad acceptor specificity and high activity can be engineered .

These findings contribute to understanding how ST6GAL1 recognizes and selects its glycoprotein substrates, which has implications for both basic research and biotechnological applications.

How does ST6GAL1-mediated sialylation affect specific receptor functions in cancer?

ST6GAL1 has been shown to modify several receptors critical to cancer progression:

• EGFR: ST6GAL1-mediated sialylation of EGFR enhances PI3K/AKT signaling, promoting invasion and proliferation in various cancers .

• E-cadherin: Overexpression of ST6GAL1 increases the turnover of cell surface E-cadherin and promotes TGF-β-induced EMT, while knockdown of ST6GAL1 strongly suppresses TGF-β-induced EMT with a concomitant increase in E-cadherin expression .

• Fcγ receptors: Terminal sialylation has been shown to decrease Fcγ receptor binding, affecting immune recognition of cancer cells .

These modifications alter receptor stability, trafficking, dimerization, and downstream signaling, ultimately contributing to cancer hallmarks such as sustained proliferation, enhanced self-renewal, EMT, invasion, and chemoresistance .

What are the most effective approaches for manipulating ST6GAL1 expression in experimental systems?

Researchers have successfully employed several strategies to modulate ST6GAL1 levels:

• Genetic approaches:

  • shRNA knockdown: Stable transduction with lentivirus expressing shRNA for ST6GAL1 has been effective in reducing endogenous ST6GAL1 in cancer cell lines .

  • Overexpression: Transient co-expression with other glycosyltransferases (e.g., GT) has been used to enhance specific glycan modifications .

• Pharmacological approaches:

  • Sialyltransferase inhibitors: The sialyltransferase inhibitor P-3F AX-Neu5Ac has been used to target α2,6 sialylated N-glycans expressed by prostate cancer cells .

• Expression system considerations:

  • No significant differences in substrate recognition have been observed when soluble forms of ST6GAL1 with similar peptide sequences were produced in either yeast or mammalian cells, confirming that heterologous expression does not alter enzyme folding and activity .

How can researchers analyze ST6GAL1 expression and activity in tissue samples?

Multiple complementary techniques are recommended for comprehensive analysis:

• Expression analysis:

  • Immunohistochemistry: Using ST6GAL1-specific antibodies has revealed differential expression patterns in normal versus cancer tissues. For example, in normal and cirrhotic liver, ST6GAL1 was localized in the Golgi region of hepatocytes surrounding the bile canaliculi, while HCC showed Golgi and diffuse cytoplasmic staining .

  • Western blotting: Can detect ST6GAL1 protein levels, typically appearing at approximately 64 kDa under reducing conditions .

  • qRT-PCR: For quantitative analysis of ST6GAL1 mRNA expression.

• Activity and glycan analysis:

  • MALDI imaging mass spectrometry (MALDI-IMS): Has been used to identify larger branched α2,6 sialylated N-glycans that show specificity to prostate tumor tissue .

  • Lectin blotting: Using SNA (Sambucus nigra lectin) to detect α2,6-sialylated glycans and MALII (Maackia amurensis lectin II) to detect α2,3-sialylated glycans .

  • Flow cytometry: Using recombinant fusion proteins of CD22 and sialoadhesin that recognize α2,6- or α2,3-sialylated glycans .

What are the key considerations when using recombinant ST6GAL1 for in vitro sialylation studies?

Researchers should consider several factors to optimize in vitro sialylation experiments:

• Enzyme form selection:

  • Full-length versus truncated: Differences in transfer efficiency have been observed between membrane and soluble enzymatic forms, with deletion of the transmembrane fragment inducing loss of acceptor preference .

  • Expression system: No significant differences in enzyme activity have been observed between soluble ST6GAL1 produced in yeast versus mammalian cells .

• Reaction optimization:

  • Substrate concentration: For antibody sialylation, an optimal DNA mix composition of 2% GT plasmid and 20% ST6 plasmid has been determined for efficient Fc glycan sialylation .

  • Reaction conditions: Buffer composition, pH, temperature, and incubation time need optimization for specific applications.

• Confirmation methods:

  • Multiple complementary analytical techniques should be employed to confirm successful sialylation, including mass spectrometry, lectin blotting, and electrophoresis-based methods .